Aeterna Zentaris to Present at the H.C. Wainwright Global Life Sciences Conference

Rhea-AI Summary

Aeterna Zentaris Inc. (NASDAQ: AEZS) announced that Dr. Klaus Paulini, CEO, will present at the H.C. Wainwright Global Life Sciences Conference on March 9-10, 2021. The event will feature a video webcast available on-demand starting March 9 at 7:00 AM ET. Aeterna is known for its lead product, macimorelin, the only FDA and European Commission approved oral test for adult growth hormone deficiency. The Company is also working to commercialize macimorelin in various markets, including Europe and Israel.

CHARLESTON, S.C., Feb. 24, 2021 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (the “Company”), a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests, today announced that Dr. Klaus Paulini, Chief Executive Officer of Aeterna, will present at the virtual H.C. Wainwright Global Life Sciences Conference taking place March 9-10, 2021.

The video webcast presentation will be available for viewing on-demand beginning Tuesday, March 9, 2021, at 7:00 AM ET for those registered for the event and will be accessible on the Events page in the Investors section of the Company’s website (www.zentaris.com). The webcast replay will be archived for 90 days following the event.

For more information about the conference, please visit the conference website here.

About Aeterna Zentaris Inc.

Aeterna Zentaris Inc. is a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests. The Company’s lead product, macimorelin, is the first and only U.S. FDA and European Commission approved oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD). Macimorelin is currently marketed in the United States under the tradename Macrilen^™ through a license agreement with Novo Nordisk where Aeterna receives royalties on net sales. According to a commercialization and supply agreement, MegaPharm Ltd. will seek regulatory approval and then commercialize macimorelin in Israel and the Palestinian Authority. Additionally, upon receipt of pricing and reimbursement approvals, Aeterna expects that macimorelin will be marketed in Europe and the United Kingdom through a recently established license agreement with Consilient Health Ltd. and Aeterna will receive royalties on net sales and other potential payments.

The Company is also leveraging the clinical success and compelling safety profile of macimorelin to develop it for the diagnosis of childhood-onset growth hormone deficiency (CGHD), an area of significant unmet need.

The Company is actively pursuing business development opportunities for the commercialization of macimorelin in Asia and the rest of the world, in addition to other non-strategic assets to monetize their value. For more information, please visit www.zentaris.com and connect with the Company on Twitter, LinkedIn and Facebook.

Forward-Looking Statements

This press release contains forward-looking statements (as defined by applicable securities legislation) made pursuant to the safe-harbor provision of the U.S. Securities Litigation Reform Act of 1995, which reflect our current expectations regarding future events. Forward-looking statements in this press release include those relating to Aeterna’s expectation that, upon receipt of pricing and reimbursement approvals, macimorelin will be marketed in Europe and the United Kingdom. Forward-looking statements involve known and unknown risks and uncertainties, and other factors which may cause the actual results, performance or achievements stated herein to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information. Actual results could differ materially from those currently anticipated due to a number of factors and risks, including, without limitation, our ability to obtain receipt of pricing and reimbursement approvals as well as those risks discussed in our Annual Report on Form 20-F, under the caption "Key Information -Risk Factors" filed with the relevant Canadian securities regulatory authorities in lieu of an annual information form and with the U.S. Securities and Exchange Commission. Given the uncertainties and risk factors, readers are cautioned not to place undue reliance on these forward-looking statements. We disclaim any obligation to update any such factors or to publicly announce any revisions to any of the forward-looking statements contained herein to reflect future results, events or developments, unless required to do so by a governmental authority or applicable law.

Investor Contact:

Jenene Thomas
JTC Team
T (US): +1 (833) 475-8247
E: aezs@jtcir.com

FAQ

What is Aeterna Zentaris presenting at the H.C. Wainwright Global Life Sciences Conference?

Aeterna Zentaris will be presenting information about its products and business strategy at the H.C. Wainwright Global Life Sciences Conference on March 9-10, 2021.

When will the video webcast of Aeterna Zentaris' presentation be available?

The video webcast will be available on-demand beginning March 9, 2021, at 7:00 AM ET.

What is macimorelin, and why is it significant for Aeterna Zentaris?

Macimorelin is Aeterna's lead product, the first and only oral test approved for diagnosing adult growth hormone deficiency, which plays a crucial role in the Company's portfolio.

How is Aeterna Zentaris expanding the commercialization of macimorelin?

Aeterna is pursuing regulatory approvals to market macimorelin in Europe and Israel and is exploring business development opportunities in Asia and other markets.

What is the stock symbol for Aeterna Zentaris?

The stock symbol for Aeterna Zentaris is AEZS.